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The purpose of this study was to assess the psychological distress of cancer patients in a disease-specific manner as well as the
demographic and medical variables that have an impact on the distress. Psychological distress was assessed with the Questionnaire on
Stress in Cancer Patients revised version, which has been developed and psychometrically evaluated in Germany. It consists of items
about 23 cancer-specific stress situations, which have to be answered in terms of relevance and amount of distress. A heterogeneous
sample of 1721 cancer in- and outpatients was assessed. For the total group, the most important distress is the fear of disease
progression. We consider between 23.4% (ca. of the upper gastrointestinal tract) and 40.9% (breast cancer patients) as highly
distressed. The most distressed diagnostic subgroups are patients with soft tissue tumours and breast cancer patients. There are no
global (general) stress factors, as the relevant demographic and medical ‘risk factors’ varied between the diagnostic subgroups.
Cancer-specific distress questionnaires give a more precise insight into patients’ experience than general or psychiatric questionnaires.
They are not only used in large screening studies but also in routine medicine, particularly when the objective is to identify patients to
whom psycho-oncological support is to be given.
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There is much research demonstrating that cancer patients suffer
from a significant amount of psychological distress. The assess-
ment of psychological distress does not only play a role within
epidemiological/basic research but also increasingly within routine
clinical practice.
Usually ‘psychological distress’ is interpreted and assessed as
psychiatric morbidity or prevalence of psychiatric disorders,
especially anxiety disorders and depression. The prevalence rate
for psychiatric disorders in general among cancer patients varies
between 5 and 50%, for depressive disorders between 0 and 46%
and for anxiety disorders between 1 and 49% (Derogatis et al,
1983; van’t Spijker et al, 1997; Sellick and Crooks, 1999; Ha ¨rter
et al, 2001; Zabora et al, 2001a). The most frequently used
screening instruments on which these findings are based are the
Profile of Mood States (POMS; McNair et al, 1992), the Symptom
Checklist (SCL-90-R; Derogatis, 1977) or its short form, the Brief
Symptom Inventory (BSI; Derogatis, 1993), the State Trait Anxiety
Inventory (STAI; Spielberger et al, 1970), the Hospital Anxiety and
Depression Scale (HADS; Moorey et al, 1991), the General Health
Questionnaire (GHQ; Goldberg and Williams, 1988) and the
Sickness Impact Profile (SIP; Bergner et al, 1981).
These questionnaires are either psychiatric or unspecific
instruments. They have not been developed for cancer patients.
(In the field of quality of life research, cancer-specific ques-
tionnaires are used, for example, the EORTC Quality of Life
Questionnaire QLQ C30 (Aaronson, 1991) or the Functional
Assessment of Cancer Therapy, FACT (Cella et al, 1993)).
The application of such tests within oncology does not give
adequate insight into the subjective health of tumour patients.
On the one hand, tumour patients are asked questions that have
little relevance for most of them (psychiatric symptom items) and
on the other hand, the specific needs and distress of such chronic
physically ill are only insufficiently recognised, for example, real,
non-neurotic fears, communication disorders, feelings of physical
imperfection, somatic and social consequences as a result of
treatment (Lee-Jones et al, 1997; Stark et al, 2002).
This makes for a distorted picture, for instance, in patients
whose psychological findings are not consistent with those of a
psychiatric disorder but nevertheless exhibit signs of high
subjective distress and require psychosocial support.
In general, disease-specific questionnaires deliver results
that more adequately mirror the experiences of the patient;
they are more clinically relevant, because they more clearly
pinpoint (psychooncological) treatment consequences (Thewes
et al, 2004).
We present findings from a large German cross-sectional
screening study that are based on a measuring instrument
specifically developed to determine psychosocial stress in cancer
patients, the Questionnaire on Stress in Cancer Patients revised
version (QSC-R23; Herschbach et al, 2003). The purpose of this
Received 29 January 2004; revised 5 May 2004; accepted 13 May 2004;
published online 6 July 2004
*Correspondence: Prof. Dr P Herschbach, Institut fu ¨r Psychosomatische
Medizin, Medizinische Psychologie und Psychotherapie der TU-Mu ¨nchen,
Langerstr. 3, 81675 Mu ¨nchen, Germany;
E-mail: P.Herschbach@lrz.tum.de
British Journal of Cancer (2004) 91, 504–511
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
lstudy was to assess cancer-specific stress situations and to identify
demographic and medical variables that are related to the
psychological distress.
MATERIALS AND METHODS
Subjects and procedure
The total sample comprises subsamples that come from different
regions within Germany and have been treated at different stages
of treatment in various treatment settings, for example, public
hospitals, university clinics, rehabilitation clinics, outpatient
clinics, in addition to a subsample of patients who have been
contacted at home (follow-up investigation). All patients were
informed of the objectives of the study and that participation was
voluntary. After being given instructions, they then completed the
questionnaire on their own.
Data collection
Psychological distress was assessed with the ‘Questionnaire on
Stress in Cancer Patients revised version’ QSC-R23 (Herschbach
et al, 2003; see attachment). The QSC is a disease-specific
questionnaire to assess psychosocial stress in cancer patients (all
diagnoses and treatment settings). It contains 23 items that
describe potential everyday stress in all areas of life in detail and in
everyday language. Each problem has to be answered twice: does it
apply to the test person at present and – if it does apply – to what
extent does this problem cause distress? The range of the response
categories varies between 0 (¼the problem does not apply to me)
and 5 (¼the problem applies to me and is a very big problem).
The items are grouped into five homogeneous scales: psychoso-
matic complaints, fears, information deficits, everyday life
restrictions and social strains.
The development of the QSC took place in Germany and was
carried out in several phases, including detailed interviews and
preliminary test versions (Herschbach et al, 1985; Herschbach and
Henrich, 1987) and psychometric evaluations (Herschbach et al,
2003). The construct validity has been demonstrated by correlation
analysis with diverse psychological tests such as HADS depression
(r¼0.75, n¼578), HADS anxiety (r¼0.73, n¼579) or SCL-90-R
(r¼0.76, n¼171). The discriminant validity and the sensitivity to
change has also been demonstrated (Herschbach et al, 2003). The
reliability has been analysed via Cronbach’s alpha, which is 0.89
(n¼1349) for the total score.
Statistical analyses
Statistical evaluation was performed using the Statistical Package
for Social Sciences program (SPSS; Version 10.0). Group
differences were tested with t-tests or F-tests. To verify the cutoff
point 41.5 of QSC-R23 total score, a receiver–operator char-
acteristic curve analysis was performed with anxiety and depres-
sion as categorical variables measured with the Hospital Anxiety
and Depression Scale (recommended cutoff values 411; Moorey
et al, 1991), a questionnaire which is widely used in oncology. We
used the Youden index (sensitivityþspecificity 1) as a measure
of accuracy (Youden, 1950).
To identify the proportion of ‘risk patients’ in different
subgroups within each diagnostic group, we used CHAID (‘CHi-
squared Automatic Interaction Detector’), which is part of
AnswerTree (SPSS). The CHAID is a multivariate exploratory
technique and a nonparametric alternative to the hierarchical
regression approach. In contrast to the regression approach,
CHAID has no restrictions regarding the measurement level or the
frequency distribution of the variables. It is concerned with the
discovery and specification of population subgroups that differ in
their probability of an event (using chi square tests). This event is,
in our case, the association of the patients to the group of ‘highly
distressed’ or ‘risk patients’.
In the first step, CHAID examines the categories of each
predictor for significance with respect to the dependent variable in
the total sample. If possible and useful, categories are merged with
others. Continuous predictors (such as age or illness duration) are
analysed for one or more single cutoff values to split the sample.
Finally, the most significant predictor is selected for segmenting
the sample. In the next step, CHAID moves down the tree, splitting
on the best predictor, and analyses each subgroup in turn. This
process is continued until there is no significant predictor
(P40.010), or the specified stopping rules are fulfilled (e.g.
minimum number of cases in a subgroup¼10).
RESULTS
Sample
The total sample comprises 1721 cancer patients (cf. Table 1). Most
patients are between 50 and 69 years old; 56.1% are female.
Table 1 Sample description
n %
Age(years)
o 40 231 13.7
40–49 292 17.3
50–59 507 30.0
60–69 397 23.5
4 69 264 15.6
Gender
Female 958 56.1
Male 750 43.9
Partnership
With partner 1107 75.3
Without partner 363 24.7
Cancer diagnoses
Breast 394 22.9
Haematological neoplasias 326 18.9
Gynaecological carcinomas 236 13.7
Upper gastrointestinal tract 145 8.4
Respiratory tract 124 7.2
ENT
a carcinomas 117 6.8
Lower gastrointestinal tract 108 6.3
Male genitourinary tract 99 5.8
Urinary tract 45 2.6
Brain tumours 42 2.4
Soft tissue tumours 32 1.9
Thyroid carcinomas 14 0.8
CUP
b, other diagnoses 21 1.2
Missing diagnoses 18 1.0
Metastases
Yes 407 29.2
No 986 70.8
Illness duration
o 6 months 677 46.9
6 months–2 years 353 24.5
42 years–5 years 247 17.1
45 years 166 11.5
Treatment setting
Inpatient clinic 1090 63.4
Rehabilitation center 425 24.7
Outpatient settings 11 0.5
No actual treatment 194 11.3
aEar, nose and throat.
bCancer with unknown primary tumour.
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lThere is a wide range of 12 different diagnostic subgroups. The
most frequent were breast cancer (22.9%), haematological
neoplasias (18.9%) and gynaecological cancers (13.7%). A total
of 21 patients had cancers of unknown primary tumour (CUP) or
very rare diagnoses and 18 patients were without diagnosis
(missing). In all, 1090 patients were recruited in hospitals, 425 in
rehabilitation centres and 11 in outpatient settings. A total of 194
persons were not undergoing treatment at the time of assessment;
they were contacted by mail during a follow-up study.
Psychosocial distress
The results are presented in the following order. First of all, we
look at the stress scores (items and scales of the QSC-R23) for the
total sample. Then, we present the variables that have a significant
impact upon the total stress score of the QSC-R23 in the total
sample (univariate subgroup comparisons) and finally we look at
the relevant variables for each diagnostic category separately
(multivariate analyses).
The ranked mean stress scores of the 23 items of the QSC-R23
questionnaire (see the appendix) for the total sample are presented
in Table 2 (first column). A very broad spectrum of problems and
burdens is mapped here. It contains physical and psychological
complaints, fears, social problems, information deficits, etc.
The third column shows the percentage of patients who used the
highest response categories (strongly/very strongly distressed). As
can be seen, the most frequent problems are the fear of disease
progression (32.2%), of not being able to follow one’s hobbies
(24%) and the fear of having to go to hospital again (23.2%).
The mean scores for the five subscales are: fears M¼1.94
(s.d.¼1.40), psychosomatic complaints M¼1.57 (s.d.¼1.13),
everyday life restrictions M¼1.40 (s.d.¼ 1.16), information
deficits M¼0.80 (s.d.¼ 0.96) and social strains M¼0.61 (s.d.¼
0.84). The total score is M¼1.26 (s.d.¼0.83).
Univariate subgroup comparisons
In order to find out which medical and sociodemographic factors
have an impact on the distress of the patients (QSC-R23 total
score), we looked at the variables age, gender, partnership,
diagnoses, metastases (yes/no), illness duration and treatment
setting. Table 3 and Figure 1 show the corresponding subgroup
comparisons.
All the variables, with the exception of partnership, have a
significant impact on the patient’s distress.
The results of the variable diagnoses are presented in Figure 1.
Patients with soft tissue tumours and breast cancer patients have
the highest stress scores; patients with the lowest scores are those
with tumours of the GI tract and with tumours of the urinary tract.
The subgroup differences are significant (P¼0.002).
Multivariate subgroup comparisons
The last step in our evaluation includes multivariate subgroup
comparisons. The statistical procedure we used here is CHAID.
The dependent variable in CHAID is the association of the patients
to the dichotomised QSC-R23 total score. We used a cutoff point at
the 66th percentile, that is, all patients with a QSC-R23 total score
41.5 are considered as ‘highly distressed’ or ‘risk patients’.
The reason for choosing this cutoff point is that in most of the
relevant studies, the proportion of highly stressed cancer patients
varies between 25 und 30% (van’t Spijker et al, 1997; Weis and
Koch, 1998; Sellick and Crooks, 1999; Ha ¨rter et al, 2001; Zabora
et al, 2001a). Additionally, we made an attempt to validate this
cutoff point. We used data from an independent QSC-R23 data file
(n¼596), which also contains data from the HADS. The ROC
analyses revealed an optimum cutoff 41.69 for the QSC-R23 total
score (sensitivity 88%, specificity 72%, Youden index 0.599) to
classify depression and a cutoff 41.64 (sensitivity 90%, specificity
71%, Youden index 0.611) to classify anxiety. These values are
close to 1.5 and justify the use of this cutoff point.
Table 2 Stress scores of the single items of the QSC-R23
a
M s.d. % 4/5
Being afraid of disease progression 2.41 1.80 32.2
Feeling tired and weak 2.06 1.68 22.3
Being afraid of having to go to the hospital again 1.92 1.78 23.2
Not being able to follow one’s hobbies 1.91 1.79 24.0
Being afraid of developing pain 1.77 1.73 20.9
Having trouble sleeping 1.76 1.74 20.7
Feeling often tense and nervous 1.75 1.58 16.2
Being afraid of not being able to work anymore 1.66 1.83 21.3
Going out less 1.46 1.70 17.2
Having sex less frequently 1.45 1.71 16.0
Feeling physically imperfect 1.34 1.66 15.0
Suffering pain due to surgery 1.19 1.49 9.8
Suffering pain due to unknown causes 1.10 1.52 0.1
Feeling not adequately informed about social
support
0.98 1.51 10.8
Feeling not well informed about illness/treatment 0.84 1.37 7.3
Body care has become difficult 0.80 1.37 7.8
Difficulty for partner to empathise my situation 0.70 1.27 5.6
Having too few opportunities to talk about
emotional problems
0.69 1.29 6.5
Different information from different doctors 0.68 1.31 6.5
Feeling unconfident in relationships with other
people
0.66 1.21 4.9
Having the feeling of being less value for other
people
0.57 1.19 5.3
Difficulty in talking with the family 0.55 1.19 5.3
Other people react inconsiderately/
unsympathetically
0.55 1.13 4.3
aQuestionnaire on Stress in Cancer Patients – revised version.
Table 3 QSC-R23 total score for subgroups of cancer patients
M s.d. P
Age
o 40 1.25 0.86
40–49 1.36 0.89 o0.001
50–59 1.34 0.81
60–69 1.20 0.79
469 1.05 0.77
Gender
Female 1.32 0.85 o0.001
Male 1.18 0.79
Partnership
With partner 1.22 0.80 0.823
Without partner 1.23 0.90
Metastases
Yes 1.35 0.83 0.002
No 1.21 0.80
Illness duration
o 6 months 1.15 0.78
6 months–2 years 1.34 0.87 o0.001
42 years–5 years 1.34 0.83
4 5 years 1.18 0.83
Treatment setting
Inpatient clinic 1.22 0.81
Rehabilitation center 1.39 0.82 0.002
Outpatient settings 1.45 0.87
No actual treatment 1.17 0.91
Cancer distress
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lSix medical or sociodemographic variables were analysed as
potential predictors of the QSC-R23 cutoff score for the ‘risk
group’: age, gender, partnership, metastases, illness duration and
treatment setting. We looked at the impact of medical or
sociodemographic factors separately within each diagnostic
subgroup that included at least 99 patients: breast cancer
(n¼394); gynaecological cancer (n¼236); ENT carcinomas
(n¼117); haematological neoplasias (n¼326), upper GI tract
(n¼145), lower GI tract (n¼108), respiratory tract (n¼412) and
male genitourinary tract (n¼99).
The CHAID results are presented for each of those diagnostic
groups as figures (Figures 2–7). The figures show the relevant
predictors and categories (P-value included) and the number and
percentage of ‘risk patients’ within each subgroup. The P-values
o0.10 were regarded as significant.
Breast cancer
In total, 40.9% of the 394 breast cancer patients belong to the risk
group (Figure 2). The most important predictor is age. Patients
under 57 years of age are more stressed than the older patients.
The most stressed subsample is made up of younger patients with
metastases. The proportion of risk patients here is 69.2%.
Gynaecological cancer
A total of 236 patients have gynaecological cancer; 35.2% are in the
risk group (Figure 3). The only significant predictor variable is
illness duration. The proportion of risk patients is highest in the
subgroup of patients with an illness duration of more than 6
months (47.7%).
Ear, nose and throat cancer
In all, 32.5% of all ENT patients belong to the risk group. This
proportion goes up to 50.0% in the subgroup of female patients.
Haematological neoplasias
Here, we find two significant predictors: gender and illness
duration (Figure 5). The most stressed subgroup is made up of
female patients with an illness duration of less than 5 years. The
risk proportion here is 43.9% compared to 31.0 % in the total
group.
Cancer of the lower gastrointestinal tract
This diagnostic subgroup consists of 108 patients; the risk
proportion is 28.7% (Figure 6). The most important predictor is
age. Patients under 66 years belong to the group of risk patients.
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Upper gastrointestinal tract
Urinary tract
Lower gastrointestinal tract
Male genitourinary tract
Gynaecological carcinomas
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Brain tumours
ENT carcinomas
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Figure 1 QSC-R23 total scores for the diagnostic subgroups.
Breast Ca
N = 394
________
40.9%
Age
< 57 years
N = 232
________
50.0%
Age
> 57 years
N = 162 
________
27.8%
No metastases
N = 180
_________
44.4% 
Metastases
N = 52
________
69.2%
P = 0.0001
P = 0.004
Figure 2 The CHAID analysis for breast cancer.
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lThe second predictor is the partner situation (P¼0.07). The small
group of younger patients without a partner has a high proportion
of risk patients (64.3%).
Cancer of the upper gastrointestinal tract
The only relevant predictor here is metastases (Figure 7). In
total, 23.5% of the whole group (n¼145) belong to the risk
group. The corresponding number of patients with metastases is
38.3%.
Cancer of the respiratory tract
Among the 412 patients with cancer of the respiratory tract, 37.9 %
belong to the risk group. No significant predictor could be found
in this diagnostic subgroup.
Male genitourinary tract
A total of 31.3% of the 99 patients with cancer of the male
genitourinary tract are in the risk group. Here again, no significant
predictor was found.
Summarising the CHAID results, we found that the percentage
of risk patients varies among the diagnostic subgroups between
40.9% in the breast cancer group and 23.5% in the upper
Gynaecol. Ca
N = 236
__________
35.2%
Illness duration
< 6 months
N = 150
_________
28.0%
Illness duration
> 6 months
N = 86
__________
47.7%
P = 0.02
Figure 3 The CHAID analysis for gynaecological cancers.
ENT Ca
N = 117
_______
32.5%
Gender:
male
N = 91
_________
27.5%
Gender:
female
N = 26
__________
50.0%
P = 0.03
Figure 4 The CHAID analysis for ENT (ear, nose and throat) cancer.
Haematol. neopl.
N = 326
____________
31.0%
Gender:
female
N  = 137
________
37.2%
Gender:
male
N  = 189
________
26.5%
P = 0.03
Illness duration
< 5 years
N  = 107
____________
43.9%
Illness duration
> 5 years
N  = 30
___________
13.3%
P = 0.01
Figure 5 The CHAID analysis for haematological nedoplasias.
Lower gi-tract
N = 108
___________
28.7%
Age
< 66 years
N = 65
______
38.5%
Age
> 66 years
N = 43
______
13.9%
Without 
partner
N = 14
______
64.3%
With 
partner
N = 51
_______
31.4%
P = 0.05
P = 0.07
Figure 6 The CHAID analysis for the lower gastrointestinal tract.
Cancer distress
P Herschbach et al
508
British Journal of Cancer (2004) 91(3), 504–511 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lgastrointestinal cancer group. The predictors also vary between the
diagnostic subgroups; thus we found that there are no general risk
factors for psychological distress. The younger breast cancer
patients with metastases form the most stressed single subgroup.
DISCUSSION
This is a large cross-sectional study about the psychological
morbidity of cancer patients assessed with a disease-specific
psychometrically evaluated questionnaire. We looked at the
distress profile, compared the diagnostic subgroups and analysed
risk factors for high distress within the diagnostic subgroups.
Our results are based upon a large and heterogeneous sample,
which included diverse diagnoses, disease stages and treatment
settings. For the total group of 1721 patients, the most important
single distress is the fear of disease progression (Herschbach et al,
2004). There is a significant impact upon the total stress score for
the variables age, gender, metastases, illness duration, treatment
setting and diagnoses. Patients with soft tissue tumours and breast
cancer patients have the highest stress scores. The proportion of
patients within the diagnostic subgroups, which we considered
highly distressed or as risk groups, varies between 23.5% (cancer
of the upper gi tract) and 40.9% (breast cancer).
When we look at the determinants for psychological distress
within each diagnostic category separately, we see a very
heterogeneous picture.
One important sociodemographic variable is gender. Generally
(not only in oncology), we see that females demonstrate higher
stress scores in psychological tests than males. This is also true in
our total sample as well as for the diagnostic subgroups of patients
with haematological neoplasias and ENT cancer. For the breast and
gynaecological cancer patients, the variables diagnosis and gender
are confounded. This is probably one reason for the high stress
scores of these patients. That especially for the younger breast
cancer patients the stage of disease (metastases) is an important
risk factor is very plausible.
In general, metastases are of less relevance than to be expected.
For six of the eight subgroups it does not play a major role in
subjective stress.
The illness duration is an important risk factor for the patients
with gynaecological cancers and haematological neoplasias. For
the first group, the critical time frame is the first 6 months after
diagnosis. This is the time that might here be considered a critical
marker for the further prognosis, whereas the haematological
patients with much longer treatment durations seem to orientate
themselves more to the conventional 5-year survival rate criteria.
Although we can find plausible interpretations for the relevance
of single risk factors within some diagnostic subgroups, it seems
difficult to explain why the same factors do not play the same role
within other subgroups (e.g. relevance of age for patients with
cancer of the lower gastrointestinal tract but not for patients with
cancer of the upper gastrointestinal tract). We probably need to
take into account complex interaction patterns between variables.
Also we would need larger and more homogeneous samples for
each diagnostic subgroup to have a chance to clarify these
interaction patterns.
There is a second problem with our data. Our list of potential
stress determinants is certainly incomplete. In order to match the
data from the different centres and for practical reasons, we used
only variables that could be assessed by the patients themselves.
All the objective factors that are concerned with the cancer
prognosis could therefore not be included.
We also did not consider the actual treatment situation. This is a
variable that might have an influence upon the subjective distress,
but is a very complex one. Most of the patients were undergoing
treatment at the time of our assessment. The treatment was
surgery, radiotherapy, chemotherapy or a combination of these,
for the first time or repeatedly. This variable again is confounded
with the disease stage and also the diagnosis.
For those reasons, the results may be considered preliminary.
Nevertheless, in our opinion, the differentiation of risk factors
according to diagnostic subgroups using the same cancer-specific
distress instrument has proved to be worthwhile. This does not
mean that global or psychiatric scales do not have any relevance in
oncology; they play a role in comparison or epidemiological
studies. Also, they are useful in identifying psychiatric diseases
within samples of cancer patients.
For further research, adequate sample sizes and better
controlled risk factor variables are suggested.
It is difficult to compare our results with the literature (e.g.
Ha ¨rter et al, 2001; van’t Spijker et al, 1997; Zabora et al, 2001a)
because we used a cancer-specific questionnaire rather than global
or psychiatric measures. Our data are in line with Zabora et al,
who found the highest stress scores for the BSI scales Anxiety and
Somatization, and they also found that between 29.6% (gynaeco-
logical cancers) and 43.45% (lung cancer) of the patients could be
considered severely stressed. Ha ¨rter et al found that 20% of their
patients had pathological scores for anxiety, and 17% for
depression.
If we look at the potential risk factors for severe distress (or
psychopathological test scores), we again find a rather inconsistent
picture. In some studies, the diagnostic subgroups differ (as in our
study), in others they do not (van’t Spijker et al, 1997). Usually
female patients and younger patients suffer more stress than male
or older patients, as in our study and as also shown in Ha ¨rter’s and
Zabora’s study. We also found that metastases play an important
role, but Ha ¨rter et al did not. In our study, it was the outpatients
who were more stressed, in Ha ¨rter’s study the in-patients were the
more stressed subgroup.
The reasons for such disappointing heterogeneity are presum-
ably manifold. One of the factors certainly is the different
questionnaires and the psychodiagnostic criteria.
The results of our study can naturally only serve as a reference
when it comes to clinical care. Here, it is especially important that
each individual patient to be given psycho-oncological support is
identified correctly and in time. This objective is increasingly seen
as a part of comprehensive oncological care (Weller, 2004). This is
reflected, for instance, in the Guidelines for psychosocial care in
Canada (‘Psychosocial service needs of patients and families are
assessed systematically using appropriate tools’ (Canadian Cancer
Society).), Australia, USA (‘All patients should be screened for
distress at their initial visit, at appropriate intervals, and as
clinically indicated’ (American Society of Clinical Oncology).) or
Germany (Carlson and Bultz, 2003; Mehnert et al, 2003).
Upper gi-tract
N = 145
___________
23.5%
No metastases
N = 98
___________
16.3%
Metastases
N = 47
___________
38.3%
P = 0.01
Figure 7 The CHAID analysis for the upper gastrointestinal tract.
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lIn the meantime, there are several Cancer Centres endeavouring
to implement these guidelines in their clinical care as part of
distress screening programmes, for example, the Memorial Sloan-
Kettering Cancer Centre in New York (Roth et al, 1998), the Sidney
Kimmel Comprehensive Cancer Centre at Johns Hopkins in
Baltimore (Zabora et al, 2001b), the Royal Newcastle Hospital in
Newcastle, New South Wales, Australia (Bonevski et al, 2000), the
Tom Baker Cancer Centre in Calgary, Canada (Carlson and Bultz,
2003) or the Clinical Cancer Centre, University Clinic Rechts der
Isar in Munich (Heussner et al, 2004). The use of electronic
questionnaire versions (e.g. tablet PCs or touch screen computers)
has proved to be feasible and useful in practice (Detmar and
Aaronson, 1998; Velikova et al, 1999; Cull et al, 2001). We would
suggest that unspecific psychopathology questionnaires should not
be used for this purpose, but rather questionnaires that are
relevant to the specific experiences of cancer patients and,
therefore, are of greater clinical relevancy.
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The questionnaire is provided in Table A1.
Here is a list of situations that you might encounter and that might cause you stress. For each
situation, please first decide whether the situation currently applies to you. If so, then please indicate
how much of a problem the situation is for you by making an 'X' on the five point scale "only a 
slight problem" to "a very big problem". If not, then make an 'X' under "Does not apply to me".
1.  I often feel tired and weak.
0 1 2 3 4 5
2.  I am suffering pain due to surgery.
4.  I am suffering pain due to unknows causes (headaches, lower 
     back pain, belly aches).
5.  I am afraid of a progression of my disease.
14. I am afraid of not being able to work anymore.
13. I often have trouble sleeping.
16. I am often tense and nervous.
15. I do not feel well informed about my illness/treatment.
18. I do not feel adequately informed about possibilities for
      social/financial support.
21. Different doctors gave different informations about my 
      illness.
22. I have too few opportunities to talk about emotional 
      problems with a specialist. 
10. I am afraid of having to go to the hospital again.
©
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12. I cannot follow my hobbies (e.g. sports) as much as before I
      developed cancer.
7.  Body care has become difficult since I developed cancer.
3.  I  feel unconfident in relationships with other people.
6.  Other poeple often react incinsiderate/unsympathetic.
11. I feel physically imperfect.
20. Since I developed cancer. I have been going out less (to 
      the movies, out to eat, visiting friends, etc.).
9.  I have the feeling to be of less value for other people.
23. It is difficult for my spouse/partner to empathise
      my situation.
19. It is difficult to talk with my family about my
      situation.
17. I have had sex less frequently since developing cancer.
8.  I am afraid of developing pain.
Does not apply
to me.
          Applies to me, is
only a slight              a very big
problem .................... problem QSC-R 23
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